2026-05-13
Myeloid Cure and MSD Launch Clinical Co-Development of Antibody Therapies in Autoimmune Diseases
On May 12, 2026, Myeloid Cure is hnonored to announce the signing of a joint development cooperation agreement with the MSD R&D China Innovation Collaboration Center. The two parties will collaborate on the clinical co-development of antibody therapeutics in the autoimmune disease space.
2026-04-02
Myeloid Cure Completes Over RMB 150 Million Series A Financing, Deepens Original Drug Development in Macrophage Immunotherapy
Myeloid Cure Biotechnology Co., Ltd. ("Myeloid Cure") announced the completion of its over RMB 150 million Series A financing. The round is led by Bayland Capital, with participation from Hongfeng Investment, Ruihua Capital, leading industry investment institutions and prominent industrial funds.
2025-11-11
Myeloid Cure Invited to Inaugural MSD R&D China Science Day, Signs Letter of Intent with MSD R&D China
Beijing, China, November 11, 2025 — Today, MSD China R&D Center successfully hosted the inaugural MSD R&D China Science Day in Beijing. The event brought together guests from research institutes, medical institutions, biotech enterprises and the financial sector to explore
2022-09-13
Dedicated to Novel Target and Drug R&D, China’s First Innovative Biopharma Focused on Macrophages Myeloid Cure Completes Another Tens of Millions of RMB Financing
Myeloid Cure Biotechnology Co., Ltd. recently announced the completion of a new round financing of tens of millions of RMB. Myeloid Cureis the pioneer emerging biotechnology enterprise focusing on the development of biopharmaceuticals with new targets for macrophages in the tumor microenvironment and autoimmune diseases in China
2021-06-21
Myeloid Cure announced the completion of an angel round of financing of tens of millions of RMB
Myeloid Cure is the pioneer domestic emerging biotechnology enterprise in China focusing on the development of new target drugs for macrophages. Immunotherapy drugs are currently the most important treatments for cancers and autoimmune diseases,